Full Press Release Details
Announces Publication of Meta-Analysis Citing Benefits of
Generation Mesh-Covered Carotid Stent Systems
includes clinical studies incorporating the Company's MicroNet -covered stent, the
Embolic Prevention System (EPS)
Aviv, Israel- December 18, 2018 - InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard Embolic
Prevention System (EPS) for the prevention of stroke caused by the treatment of carotid artery disease, today announced the publication
of a meta-analysis of four clinical studies involving dual layered and mesh-covered stents in the December 10, 2018 issue of JACC:
Cardiovascular Interventions. The analysis concluded that carotid artery disease (CAD) patients treated with mesh-covered
stents experienced a 30-day minor stroke rate of 1.25%, lower than 30-day minor stroke rates reported in other widely cited studies,
such as CREST and ACT 1, for patients treated with both carotid endarterectomy (CEA) and with those treated with conventional
carotid stents. Moreover, CREST and ACT 1 involved lower-risk patient populations as compared to the four studies included in
the meta-analysis, which included a higher percentage of high-risk and elderly patients.
compelling results of this independent and comprehensive meta-analysis, which includes four studies of high-risk patients treated
for carotid artery disease, add to the growing body of evidence that points to superior clinical outcomes with next generation
mesh-covered or dual layered devices versus their conventional carotid stent counterparts," said James Barry, PhD, Chief
Executive Officer of InspireMD. "As we continue to expand the commercial availability of our MicroNet -covered product,
CGuard EPS, including the submission of a U.S. IDE expected in mid-2019, we welcome additional analyses such as these that
further support the positive findings from our own studies with MicroNet-covered products."
paper is also the focus of a follow-up article, dated December 12, 2018, that appeared in the publication Medcape along
with a discussion with a leading European interventional cardiologist, Professor Harald Mudra, MD, St dtisches Klinikum,
Munich, Germany, who commented, "I think we are seeing a new milestone with these mesh-covered stents in that we can achieve
a very acceptable, low rate of complications and stroke even in high-risk patients. If confirmed in larger and longer trials,
these stents could open up a new population for carotid stenting who have previously been thought of as being too high risk for
now only use these mesh-covered stents at our center. I am convinced they are superior to conventional carotid stents. The extra
layer of mesh keeps the small particles of plaque that can be released during the stenting process from entering the circulation,"
full JACC paper can be purchased online here.
seeks to utilize its proprietary MicroNet technology to make its products the industry standard for treatment of carotid
artery disease by providing outstanding acute results and durable stroke free long-term outcomes.
common stock is quoted on the NYSE American under the ticker symbol NSPR and certain warrants are quoted on the NYSE American
under the ticker symbol NSPR.WS.
press release contains "forward-looking statements." Such statements may be preceded by the words "intends,"
"may," "will," "plans," "expects," "anticipates," "projects,"
"predicts," "estimates," "aims," "believes," "hopes," "potential"
or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are
subject to various known and unknown risks and uncertainties, many of which are beyond the Company's control, and cannot
be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking
statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) market acceptance
of our existing and new products, (ii) negative clinical trial results or lengthy product delays in key markets, (iii) an inability
to secure regulatory approvals for the sale of our products, (iv) intense competition in the medical device industry from much
larger, multinational companies, (v) product liability claims, (vi) product malfunctions, (vii) our limited manufacturing capabilities
and reliance on subcontractors for assistance, (viii) insufficient or inadequate reimbursement by governmental and other third
party payers for our products, (ix) our efforts to successfully obtain and maintain intellectual property protection covering
our products, which may not be successful, (x) legislative or regulatory reform of the healthcare system in both the U.S. and
foreign jurisdictions, (xi) our reliance on single suppliers for certain product components, (xii) the fact that we will need
to raise additional capital to meet our business requirements in the future and that such capital raising may be costly, dilutive
or difficult to obtain and (xiii) the fact that we conduct business in multiple foreign jurisdictions, exposing us to foreign
currency exchange rate fluctuations, logistical and communications challenges, burdens and costs of compliance with foreign laws
and political and economic instability in each jurisdiction. More detailed information about the Company and the risk factors
that may affect the realization of forward looking statements is set forth in the Company's filings with the Securities
and Exchange Commission (SEC), including the Company's Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q.
Investors and security holders are urged to read these documents free of charge on the SEC's web site at http://www.sec.gov.
The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information,
future events or otherwise.